- Home
- ORIQ vs INKT Comparison
ORIQ vs INKT Comparison
Compare ORIQ & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ORIQ | INKT |
|---|---|---|
| Founded | 2024 | 2017 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.0M | 70.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | ORIQ | INKT |
|---|---|---|
| Price | $10.24 | $11.66 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | 22.6K | ★ 46.5K |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.01 | $6.66 |
| 52 Week High | $10.24 | $76.00 |
Technical Indicators
Market Signals| Indicator | ORIQ | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 62.03 | 50.64 |
| Support Level | $10.17 | $10.88 |
| Resistance Level | N/A | $12.58 |
| Average True Range (ATR) | 0.01 | 1.06 |
| MACD | 0.00 | -0.10 |
| Stochastic Oscillator | 100.00 | 26.18 |
Price Performance
Historical ComparisonAbout ORIQ Origin Investment Corp I Ordinary Shares
Origin Investment Corp I is a blank check company.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.